Business Update

TORI inks agreement with company formerly known as ChromaVision

Published in Cancer Weekly, May 10th, 2005

Clarient, Inc., (CLRT) announced that it has entered into an agreement with Translational Oncology Research International (TORI) under which Clarient's BioAnalytical Services business unit will provide various biopharmaceutical research services for TORI-sponsored studies.

TORI is devoted to evaluating agents for cancer treatment. Clarient, formerly known as ChromaVision Medical Systems, is a provider of automated cell-imaging systems and advanced oncology laboratory services.

"We are delighted with the opportunity to offer our lab services expertise and diagnostic technologies to support TORI in breast cancer clinical trials," said Kenneth D. Bauer,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry